Faulding Acquires FUDR Cancer Therapy Product From Roche.Business Editors ADELAIDE, South Australia--(BUSINESS WIRE)--Feb. 15, 2001 International pharmaceutical company, F H Faulding & Co Limited (Faulding) today announced that Faulding Pharmaceuticals, its US-based global pharmaceuticals division, has entered into an agreement to acquire the rights to the FUDR FUDR, FUdR floxuridine. FUDR see floxuridine. (TM) brand of sterile floxuridine from Hoffmann-La Roche, Inc. for a total of US$6 million. The transaction is expected to be completed within 30 days. FUDR(TM) brand of floxuridine is a lyophilised adj. 1. same as lyophilized. Adj. 1. lyophilised - used of tissue or blood or serum or other biological substances; dried by freezing in a high vacuum freeze-dried, lyophilized (freeze-dried) injectable antineoplastic drug that is indicated for use in the palliative management of gastrointestinal adenocarcinoma metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. to the liver. Sales of FUDR(TM) were interrupted in 1999. Prior to that interruption, product sales were US$6.3 million and had been growing steadily over recent years. The product was initially approved by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. in late 1970. Mr Frank Condella Jr, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Faulding Pharmaceuticals, said "The FUDR(TM) acquisition complements our existing strengths in the oncology and palliative care markets. It will be promoted by the Faulding Laboratories team which is successfully promoting the Kadian(R)brand of sustained-release morphine and the anxiety treatment Serax(R)brand of oxazepam oxazepam /ox·az·e·pam/ (ok-saz´e-pam) a benzodiazepine tranquilizer, used as an antianxiety agent and as an adjunct in the treatment of acute alcohol withdrawal symptoms. ox·az·e·pam n. in the United States." "This is an important step in establishing a branded oncology franchise and further progress in our continued pursuit of a targeted brand business, complementing our strength in generic pharmaceuticals," Mr Condella added. Manufacture of the product will be transferred during 2001 from Hoffmann-La Roche's site to Faulding's facility located in Mulgrave, Victoria. Faulding is a worldwide health and personal care company, listed on the Australian Stock Exchange Australian Stock Exchange (ASX) Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. . Faulding's principal businesses are oral and injectable pharmaceuticals, consumer health products, the provision of distribution and retail management services to pharmacies and logistics management services to hospitals. Faulding products are sold in over 70 countries. FUDR(TM) is a trade mark of Hoffmann-La Roche, Inc Kadian(R) is a registered trade mark of F H Faulding & Co Limited Serax(R) is a registered trade mark of American Home Products Corporation |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion